Literature DB >> 29157613

Castleman Disease Pathogenesis.

David C Fajgenbaum1, Dustin Shilling2.   

Abstract

Castleman disease (CD) describes a group of heterogeneous disorders with common lymph node histopathologic features, including atrophic or hyperplastic germinal centers, prominent follicular dendritic cells, hypervascularization, polyclonal lymphoproliferation, and/or polytypic plasmacytosis. The cause and pathogenesis of the four subtypes of CD (unicentric CD; human herpesvirus-8-associated multicentric CD; polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes [POEMS]-associated multicentric CD; and idiopathic multicentric CD) vary considerably. This article provides a summary of our current understanding of the cause, cell types, signaling pathways, and effector cytokines implicated in the pathogenesis of each subtype.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Castleman disease; Cytokine storm; HHV-8; Lymphoproliferative disorder; POEMS; TAFRO

Mesh:

Substances:

Year:  2018        PMID: 29157613     DOI: 10.1016/j.hoc.2017.09.002

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  25 in total

1.  Clinical characteristics of a concurrent condition of IgG4-RD and Castleman's disease.

Authors:  Xia Zhang; Panpan Zhang; Linyi Peng; Yunyun Fei; Wei Zhang; Ruie Feng; Wen Zhang
Journal:  Clin Rheumatol       Date:  2018-06-14       Impact factor: 2.980

2.  Somatic Mutations Confer Severe Peripheral Neuropathy in POEMS Syndrome-Associated Multicentric Castleman Disease.

Authors:  Qingqing Lin; Juying Wei; Jiejing Qian; Liangshun You; Wenbin Qian
Journal:  Neurosci Bull       Date:  2020-03-12       Impact factor: 5.203

3.  Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.

Authors:  Wanying Liu; Qingqing Cai; Tiantian Yu; Paolo Strati; Frederick B Hagemeister; Qiongli Zhai; Mingzhi Zhang; Ling Li; Xiaosheng Fang; Jianyong Li; Ruifang Sun; Shanxiang Zhang; Hanjin Yang; Zhaoming Wang; Wenbian Qian; Noriko Iwaki; Yasuharu Sato; Eric Oksenhendler; Zijun Y Xu-Monette; Ken H Young; Li Yu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

4.  How we manage idiopathic multicentric Castleman disease.

Authors:  Joshua D Brandstadter; David C Fajgenbaum
Journal:  Clin Adv Hematol Oncol       Date:  2022-09

Review 5.  Clinicopathological comparison and therapeutic approach to Castleman disease-a case-based review.

Authors:  Małgorzata Wojtyś; Agnieszka Piekarska; Michał Kunc; Konrad Ptaszyński; Wojciech Biernat; Jan Maciej Zaucha; Piotr Waloszczyk; Piotr Lisowski; Bartosz Kubisa; Tomasz Grodzki
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

6.  Lung cancer combined with diffuse peritoneal and mesenteric amyloidosis detected on 18F-FDG PET/CT: A case report.

Authors:  JianJie Wang; Bin Zhao; Tianbin Song; Jidong Sun
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

7.  A Rare Presentation of Orbital Castleman's Disease.

Authors:  Ruchi Goel; Akash Raut; Ayushi Agarwal; Shweta Raghav; Sumit Kumar; Simmy Chaudhary; Priyanka Golhait; Sushil Kumar; Ravindra Saran
Journal:  Case Rep Ophthalmol Med       Date:  2020-01-03

8.  Castleman disease. Interaction with dermatopathy: Case report.

Authors:  M L A Modolin; C P Camargo; D A Milcheski; W Cintra; R I Rocha; G M Clivatti; B Nascimento; R Gemperli
Journal:  Int J Surg Case Rep       Date:  2020-07-18

9.  The first case of thrombocytopenia, anasarca, fever, renal impairment or reticulin fibrosis, and organomegaly (TAFRO) syndrome with unilateral adrenal necrosis: a case report.

Authors:  Yu Fujiwara; Kanae Ito; Akito Takamura; Kaoru Nagata
Journal:  J Med Case Rep       Date:  2018-10-08

Review 10.  AA amyloidosis associated with Castleman disease: A case report and review of the literature.

Authors:  Luca Bernabei; Adam Waxman; Gabriel Caponetti; David C Fajgenbaum; Brendan M Weiss
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.